Navigation Links
NIH Funds Synedgen to Develop a New Drug to Improve Airway Clearance
Date:9/27/2013

Claremont, CA (PRWEB) September 27, 2013

Synedgen announces the award of a National Heart Lung and Blood Institute (NHLBI) Small Business Innovation Research grant from the NIH to explore the mechanisms of a natural modified biopolymer to both reduce the viscosity of mucus and the cohesion of biofilms, potentially leading to a pulmonary treatment for patients with cystic fibrosis (CF) to enhance airway clearance and augment the activity of standard therapeutic antibiotics. In preliminary studies, this new approach to controlling molecular interactions in thick sputum and biofilms has shown significant reductions in viscosity and cohesion.

Due to a genetic defect, CF patients have thicker mucus in their lungs and respiratory tract that is very difficult to clear. The resulting accumulation of mucus allows for colonization by biofilm-producing bacteria. The combination of thick mucus and invasive bacterial biofilms can dramatically reduce lung function of CF patients. Because the biofilms provide a sheltered environment to protect bacteria from antibiotic treatments, CF patients typically suffer from persistent and recurrent lung infections.

In partnership with Dr. Steven Rowe, Associate Professor School of Medicine, University of Alabama Birmingham (UAB), and Director of the CFF Therapeutics Development Network’s Center for CFTR Detection, researchers will be assessing a new drug’s role in reducing the viscosity of patient derived sputum. Using human bronchial cell lines that have the CF defect, they will study the drug’s effect on the relationship of sputum viscosity and mucociliary clearance by assessing activity on monolayers of ciliated cells. Since the drug has already been shown to disrupt biofilms, studies to examine the combined effect of the drug with standard antibiotic treatments will explore the effects of this new drug in enhancing the antibiotic therapies used in CF patients.

“Our approach is
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Foundation for Angelman Syndrome Therapeutics (FAST) Funds Human Clinical Trial
2. QB3-Industry Biotech Startup Partnership Funds Two Projects
3. German Academic Exchange Service funds international project on spintronics
4. NSBRI Funds Cerebrotech to Accelerate Development of Brain Monitoring Device
5. Express Diagnostics to Raise Funds for American Cancer Society During Blue Earth’s Giant Days Parade
6. Kitware Receives Funds from U.S. Air Force Research Lab to Extend the Bender Toolkit for Anatomical Model Repositioning
7. Synedgen’s Synoplex® Receives FDA Indexing for Use in the Treatment of Chronic Wounds in Pachyderms
8. Synedgen Announces Issuance of Patent to Optimize Animal Health
9. Synedgen Announces Effective Treatment Against Bacterial Biofilms in Minor Animal Species
10. Scarred for Life? Synedgen Hopes Not
11. Synedgen's Synoplex® is Headed to the Lewa Wildlife Conservancy in Kenya
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... September 2, 2015 BiondVax Pharmaceuticals Ltd. ... National Institute of Allergy and Infectious Diseases (NIAID), part of ... of Health and Human Services (HHS), to launch a new ... United States in the 2015-16 timeframe. The trial ... Multimeric-001 (M-001), as a primer vaccine, which would be administered ...
(Date:9/2/2015)... ... September 02, 2015 , ... Advancing in medical ... From vital sign monitoring in ICU to 3D skull printing analysis for Neurosurgery, ... real-time clinical decisions with simultaneous access to high precision medical images and electronic ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... efficiency of their entire waste to energy process and continue to contribute to ... Major Upgrade , Temarry’s Waste to Energy process has been operating at their ...
(Date:9/2/2015)... ... September 02, 2015 , ... Genedata, a ... today unveiled Genedata Screener ® version 13.0 at ELRIG Drug Discovery 2015. ... market a rich set of new capabilities. Screener now supports High Throughput Flow ...
Breaking Biology Technology:BiondVax Announces Intent to Launch a Phase 2 Trial in the United States in Collaboration with the U.S. National Institutes of Health 2BiondVax Announces Intent to Launch a Phase 2 Trial in the United States in Collaboration with the U.S. National Institutes of Health 3Surgical Workstation Powered by 6th Gen. Intel® Core™ Skylake Processors 2Surgical Workstation Powered by 6th Gen. Intel® Core™ Skylake Processors 3Temarry Recycling’s New $100,000 Waste to Energy Renovation 2New Genedata Screener 13.0 with Support for High Throughput Flow Cytometry and DMPK Unveiled at ELRIG 2New Genedata Screener 13.0 with Support for High Throughput Flow Cytometry and DMPK Unveiled at ELRIG 3New Genedata Screener 13.0 with Support for High Throughput Flow Cytometry and DMPK Unveiled at ELRIG 4
... TRIANGLE PARK, N.C., Jan. 14, 2011 Talecris Biotherapeutics Holdings ... has established a new record date and meeting date for ... announced merger agreement under which Grifols (GRF.MC) will acquire TLCR. ... business on January 11, 2011 will be entitled to vote ...
... 14, 2011 Accuray Incorporated (Nasdaq: ARAY ), ... that it will report results for its second quarter of ... 2011 after the market closes. A conference call ... p.m. ET and will be hosted by Euan S. Thomson, ...
... Fla., Jan. 13, 2011 GeneLink, Inc. ... consumer genomics biotech company, has announced that Robert B. ... recently formed a company to distribute genetically customized products ... intends to market the product line utilizing techniques similar ...
Cached Biology Technology:Accuray Incorporated to Report Financial Results for Second Quarter of Fiscal 2011 2GeneLink Announces New Licensing Partner 2GeneLink Announces New Licensing Partner 3
(Date:8/18/2015)... Aug. 17, 2015 Research and Markets ... the "Global Biometric Authentication & Identification Market: ... & Forecast, 2015-2020" report to their offering. ... identification systems market is expected to grow at ... 2020 and generate over $25 billion (approximately) by ...
(Date:8/12/2015)... 2015  Synaptics Inc. (NASDAQ: SYNA ), ... announced that four of its fingerprint ID products, ... been named FIDO Certified™ by the Fast IDentity ... Synaptics, Natural ID™ fingerprint solutions are fully compliant ... standard and are interoperable among other products and ...
(Date:8/6/2015)... BOSTON and TELTOW, Germany ... the 2015 Siggraph Conference, SensoMotoric Instruments (SMI) ... augmented reality , based on Epson,s Moverio ... eye tracking platform. With this new solution, unprecedented quality ... multi-modal, hands-free interaction with context-sensitive displays. For the first ...
Breaking Biology News(10 mins):Global Biometric Authentication & Identification Market 2015: Focus On Modality, Motility & Application - Estimation & Forecasts to 2020 for the $25 Billion Industry 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 3SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 2SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 3
... Sacred Seeds, an international non-profit that supports plant ... and cultural knowledge, has extended its reach to ... are in Saint-Ay, France. Sacred Seeds is ... plants of medicinal and cultural significance. The program ...
... of lung edema, or fluid in the lungs, not only do ... they are also allowing water to pump in. "Usually, our ... previously believed that this pump mechanism just stopped when people had ... Hospital. "But we,ve found not only do they stop pumping fluid ...
... MD FASEB MARC (Maximizing Access to Research Careers) ... 2013 American College of Sports Medicine (ACSM) 60th Annual ... in Indianapolis, IN from May 28 June 1, ... of students, postdoctorates and scientists from underrepresented groups into ...
Cached Biology News:Missouri Botanical Garden program annouces collaboration with L'Herboretum 2MARC travel awards announced for the 2013 60th Annual ACSM Meeting & 4th World Congress 2
Sheep polyclonal to Malate Dehydrogenase ( Abpromise for all tested applications). Antigen: Full length protein - Pig heart malate dehydrogenase. Entrez Gene ID: 4190 Swiss Protein ID: P...
...
... The epitope specific for Nabeta2 ... other known proteins.,SPECIES REACTIVITIES: ... on human because the immunogen ... residues). Reactivity with other species ...
Chicken polyclonal to HAGH ( Abpromise for all tested applications). Antigen: Synthetic peptide, corresponding to N terminal amino acids 110-260 of Human HAGH. Entrez GeneID: 3029 Swiss ...
Biology Products: